Although the strategy for targeting protein transport may be unsuitable for disorders characterized by the complete loss of Tyrosinase activity, such as oculocutaneous albinism type 1A (OCA1A), it might be effective for patients with OCA1B, who have partially retained Tyrosinase activity [9]. This evidence concerns the gene TYR and oculocutaneous albinism type 1A.